These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
83 related articles for article (PubMed ID: 6642143)
1. Cell-mediated immunity in F 344 rats bearing intraocular tumors derived from human adenovirus 12-induced retinal tumor. Kobayashi M; Mukai N; Solish SP; Sawada T; Pomeroy ME Gan; 1983 Oct; 74(5):706-11. PubMed ID: 6642143 [TBL] [Abstract][Full Text] [Related]
2. Cytotoxic activity of lymphocytes from F 344 rats bearing intraocular tumor derived from human adenovirus 12-induced retinoblastoma-like cell line. Kobayashi M; Mukai N; Solish SP; Pomeroy ME Acta Pathol Jpn; 1984 Mar; 34(2):283-7. PubMed ID: 6331062 [TBL] [Abstract][Full Text] [Related]
3. Chemotherapeutic response of tumor derived from human adenovirus 12--induced retinal tumor cell line in syngeneic CDF (F 344) rats. Kobayashi M; Mukai N; Solish SP; Sawada T; Pomeroy ME Anticancer Res; 1983; 3(2):101-6. PubMed ID: 6847128 [TBL] [Abstract][Full Text] [Related]
4. Immune privilege extended to allogeneic tumor cells in the vitreous cavity. Jiang LQ; Streilein JW Invest Ophthalmol Vis Sci; 1991 Jan; 32(1):224-8. PubMed ID: 1987103 [TBL] [Abstract][Full Text] [Related]
5. A highly predictable animal model of retinoblastoma. Kobayashi M; Mukai N; Solish SP; Pomeroy ME Acta Neuropathol; 1982; 57(2-3):203-8. PubMed ID: 7124347 [TBL] [Abstract][Full Text] [Related]
6. Complement-dependent cytotoxicity in rats bearing human adenovirus type 12-induced primary retinoblastoma-like tumor in the eye. Nishida T; Mukai N; Solish SP Curr Eye Res; 1981; 1(1):53-5. PubMed ID: 6271500 [TBL] [Abstract][Full Text] [Related]
7. Retinoblastoma-like tumors induced by human adenovirus type 12 in rats. Kobayashi S; Mukai N Cancer Res; 1974 Jul; 34(7):1646-51. PubMed ID: 4600165 [No Abstract] [Full Text] [Related]
8. Impaired th1/tc1 cytokine production of tumor-infiltrating lymphocytes in a model of primary intraocular B-cell lymphoma. Touitou V; Daussy C; Bodaghi B; Camelo S; de Kozak Y; Lehoang P; Naud MC; Varin A; Thillaye-Goldenberg B; Merle-Béral H; Fridman WH; Sautès-Fridman C; Fisson S Invest Ophthalmol Vis Sci; 2007 Jul; 48(7):3223-9. PubMed ID: 17591892 [TBL] [Abstract][Full Text] [Related]
9. Termination of systemic immunity in the presence of intraocular tumors: influence of ocular immune privilege on tumor vaccines. Chen PW; Ksander BR Curr Eye Res; 2006 Jan; 31(1):43-55. PubMed ID: 16421019 [TBL] [Abstract][Full Text] [Related]
10. Retinal tumor induction by ocular inoculation of human adneovirus in 3-day-old rats. Mukai N; Murao T J Neuropathol Exp Neurol; 1975 Jan; 34(1):28-35. PubMed ID: 1117320 [TBL] [Abstract][Full Text] [Related]
11. Successful immunotherapy of an intraocular tumor in mice. Schurmans LR; den Boer AT; Diehl L; van der Voort EI; Kast WM; Melief CJ; Toes RE; Jager MJ Cancer Res; 1999 Oct; 59(20):5250-4. PubMed ID: 10537305 [TBL] [Abstract][Full Text] [Related]
12. In vitro and in vivo growth of an intraocular retinoblastoma-like tumour in F-344 rats. Winther J Acta Ophthalmol (Copenh); 1986 Dec; 64(6):657-63. PubMed ID: 3811879 [TBL] [Abstract][Full Text] [Related]
17. Response of retinoblastoma with vitreous tumor seeding to adenovirus-mediated delivery of thymidine kinase followed by ganciclovir. Chévez-Barrios P; Chintagumpala M; Mieler W; Paysse E; Boniuk M; Kozinetz C; Hurwitz MY; Hurwitz RL J Clin Oncol; 2005 Nov; 23(31):7927-35. PubMed ID: 16258092 [TBL] [Abstract][Full Text] [Related]
18. Local T helper cell signals by lymphocytes infiltrating intraocular tumors. Ksander BR; Acevedo J; Streilein JW J Immunol; 1992 Mar; 148(6):1955-63. PubMed ID: 1531848 [TBL] [Abstract][Full Text] [Related]
19. In vitro induction of cytotoxicity against syngeneic mastocytoma and its suppression by spleen and thymus cells from tumor-bearing mice. Takei F; Levy JG; Kilburn DG J Immunol; 1976 Feb; 116(2):288-93. PubMed ID: 814160 [TBL] [Abstract][Full Text] [Related]
20. A novel treatment for ocular tumors using membrane FasL vesicles to activate innate immunity and terminate immune privilege. Gregory MS; Koh S; Huang E; Saff RR; Marshak-Rothstein A; Mukai S; Ksander BR Invest Ophthalmol Vis Sci; 2005 Jul; 46(7):2495-502. PubMed ID: 15980241 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]